

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Fig. 1a




Figure 1a: Liver araCTP levels, when Compound A and Compound B are administered at a dose of 100 mg/kg CE to male NIH Swiss mice by a single i.p. bolus injection at time 0.

Fig. 1b




Figure 1b: Plasma prodrug levels, when Compound A and Compound B are administered at a dose of 100 mg/kg CE to male NIH Swiss mice by a single i.p. bolus injection at time 0.

Fig. 1c




Figure 1c: Plasma AraC levels, when Compound A and Compound B are administered at a dose of 100 mg/kg CE to male NIH Swiss mice by a single i.p. bolus injection at time 0.

Fig. 2a




Figure 2a: Liver ara-CTP levels in rat after prodrug administration by continuous i.v. infusion. Time course of liver araCTP levels in two independent studies evaluating activation of Compound A, B or C.

Fig. 2b




Figure 2b: Dose response of liver araCTP after treatment with Compound A or Compound B.

Fig. 3a




Figure 3a: Body weight, expressed as a percent of initial weight, as a function of time in mice treated with araC at doses of 30-1000 mg/kg CE for 5 days by daily IP injection.). The * indicates $p < 0.05$ compared with vehicle.

Fig. 3b




Figure 3b: Body weight, expressed as a percent of initial weight, as a function of time in mice treated with Compound C at doses of 30-1000 mg/kg CE for 5 days by daily IP injection.

Fig. 4a




Figure 4a: Hematology endpoints after 5-day treatment with araC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The * indicates $p < 0.05$ compared with vehicle. Nucleated bone marrow cells.

Fig. 4b




Figure 4b: Hematology endpoints after 5-day treatment with araC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The * indicates $p < 0.05$ compared with vehicle. Peripheral blood multinucleated cells (PMN's).

Fig. 4c




Figure 4c: Hematology endpoints after 5-day treatment with araC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The * indicates $p < 0.05$ compared with vehicle. Peripheral blood mononuclear cells.

Fig. 4d




Figure 4d: Hematology endpoints after 5-day treatment with araC (open circles) or Compound C (closed circles) relative to saline vehicle (closed squares). The * indicates $p < 0.05$ compared with vehicle. Platelets.